Stock Ratings / Health Care / CGTX / financials

GRML (32) CRDF (41) NMRA (42) CSBR (22) ⌘ Pro Terminal →

Cognition Therapeutics Inc. (CGTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.70 -5.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.69

Cognition Therapeutics Inc. (CGTX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $70.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CGTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Cognition Therapeutics Inc. (NASDAQ: CGTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.70 (-5.57% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CGTX ranks #464 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CGTX compare to GRML and CRDF in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRML (Greenland Mines Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, CGTX leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CGTX?

▼

Per CGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001455365), Cognition Therapeutics Inc. generated $0 in revenue, -$23.5M in net income, and -$24.6M in free cash flow against $48.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.69 (-1.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY CGTX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.88-17% Next Q

Q2 (-2Q)

Grade D$0.73-1.4% Next Q

Q3 (-1Q)

Grade D$0.72-2.8% Next Q

Current

Grade D-$0.70-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CGTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CGTX currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.91) and Max Pain ($0.74) forces dealer call-delta covering toward $1.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CGTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CGTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-1.2%	-$23.5M	-$24.6M	-45%
FY 2024	$4.00B	52%	-1.3%	-$34.0M	-$28.5M	-45%
FY 2023	$4.00B	52%	-1.3%	-$25.8M	-$16.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CGTX)

✓Walkthrough of CGTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.44%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.72H $0.72L $0.64C $0.70VOL 557.5K

RES: $1.01SUP: $0.64SMA50: $0.91SMA200: $1.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGTX Butterfly Map → + Track CGTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CGTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CGTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGTX)

Health Care Rank #464 of 1016 ⚔️ GRML vs CGTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGTX vs. GRML, CRDF, NMRA, CSBR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cognition Therapeutics Inc. (CGTX) ranks #464 by composite RQD confidence (43/100, grade D-) and #707 by equity capitalization ($70.3M). Within this direct 5-issuer industry benchmark cohort, CGTX leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CGTX ACTIVE Cognition Therapeutics Inc.	D-	43/100	—	—	-35.0%	-5.57%	$70.3M	Benchmark Subject
GRML Greenland Mines Ltd.	E	32/100	—	—	-35.0%	-10.89%	$70.3M	/grml-vs-cgtx →
CRDF Cardiff Oncology Inc.	D-	41/100	—	—	-35.0%	-2.46%	$70.9M	/crdf-vs-cgtx →
NMRA Neumora Therapeutics Inc.	D-	42/100	—	—	-35.0%	-5.43%	$73.0M	/nmra-vs-cgtx →
CSBR Champions Oncology Inc.	E	22/100	—	48.0%	-26.9%	0.00%	$66.9M	/csbr-vs-cgtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001455365

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cognition Therapeutics Inc. (CGTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$23.5M, operating cash flow of -$24.6M, and free cash flow of -$24.6M (+13.7% YoY). On the balance sheet, CGTX closed FY2025 with $48.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$23.5M	-$24.6M	-$24.6M	$48.4M	—
FY2024 (FY)	2024-12-31	$0	-$34.0M	-$28.5M	-$28.5M	$30.2M	—
FY2023 (FY)	2023-12-31	$0	-$25.8M	-$16.0M	-$16.0M	—	—

3. CGTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CGTX compare to GRML and CRDF in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CGTX?

Where is CGTX trading relative to its 50-day, 200-day, and 52-week technical levels?

CGTX last traded at $0.70 (-5.57% on volume of 557,812 shares), positioning the stock -23.08% below its 50-day simple moving average ($0.91) and -34.58% below its 200-day simple moving average ($1.07). Across its 52-week range of $0.55 to $1.83, CGTX sits at the 11.7% percentile with a 14-day RSI of 33.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.79).

CGTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Cognition Therapeutics Inc. (CGTX)?

In FY 2025 (10-K), CGTX converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CGTX RQD Cockpit CGTX 12M Forecast CGTX Earnings & Move CGTX Dividends & DRIP CGTX Insiders & 13F CGTX Whale Options CGTX Profit Sankey CGTX News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CGTX — Cognition Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1

As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Cognition Therapeutics Inc. (CGTX) carries a composite score of 43 / 100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow).\n- Fundamental Cash Engine (6 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of 0.00% and gross margin of 0.0%.\n- Institutional 13F Whale Flow (12 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Biological Products (No Diagnostic Substances) cohort.\n- Insider & Congressional Conviction (5 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (10 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (10 / 20): Altman Z-Score of 2.50, Piotroski F-Score of 2/9, and Debt-to-Equity of 0.50.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %	\n	---	---	---	---	---	---	---	---	---	---	\n	$0.70	$70.3M	N/A	N/A	N/A	N/A	0.00%	1.00	$0.55 - $1.83	-35.0%

Business & Sector Positioning

Cognition Therapeutics Inc. (CGTX) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Biological Products (No Diagnostic Substances) with a market capitalization of $0.1B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), CGTX exhibits an operating margin of 0.0% and net margin of 0.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (0.0%), and valuation discipline (current multiple) relative to free cash flow conversion.

Open Questions for Prospective Investors

How sustainable is CGTX's current operating margin (0.0%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Biological Products (No Diagnostic Substances)?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 2.50)?

CGTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cognition Therapeutics Inc. (CGTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CGTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 2h ago

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

-- Conference Call and Webcast 8:30 a.m. ET November 5 -- PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat n

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, ha

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints

The planned registrational study is expected to enroll participants with mild-to-moderate DLB who will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine months."Over the

Read Full Source ↗

🔴 RISK WATCH Yahoo • 20d ago

Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a new composition of matter patent from the US Patent and Trademark Office (USPTO) covering a crystalline form of its investigational drug candidate zervimesine (CT

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 20d ago

Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045

- An additional five years of patent protection may be possible through a standard extension -PURCHASE, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX),

Read Full Source ↗

🟢 CATALYST Benzinga • 20d ago

Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine

The patent has a natural expiration of 2045. Upon zervimesine’s approval by the U.S. Food and Drug Administration (FDA), the patent may be eligible for an extension of up to five additional years.The patent, titled

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CGTX Bull vs. Bear Conversation Board — What's Your Call at $0.70?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CGTX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.62 (-11.4%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CGTX (D- • RQD 43/100) a Buy at $0.70?

Welcome to the CGTX (Cognition Therapeutics Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.54 (-22.9%)

Spot @ $0.70

Pump the brakes on CGTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CGTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cognition Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.81 (+15.7%)

Spot @ $0.70

CGTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CGTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.70 (52-wk range $0.55 - $1.83), any beat on forward guidance forces shorts and underweight funds to chase.